Actinium Pharmaceuticals Inc (ATNM)

[oldstocks]

Actinium is advancing a pipeline of differentiated, clinical-stage targeted radiotherapeutics including Iomab-B for
bone marrow transplant conditioning, which met the primary endpoint in the Phase 3 SIERRA trial and is being prepared
for a BLA filing, Iomab-ACT for conditioning prior to cell and gene therapy and Actimab-A as a therapeutic for relapsed
or refractory acute myeloid leukemia that has shown backbone therapy potential in combinations. Actinium is also
advancing novel solid tumor programs leveraging its industry leading experience with the alpha-particle payload
Actinium-225 and intellectual property including linker technology and Actinium-225 manufacturing.